WO2017173960A1 - Macro-hétérocycle utilisé pour supprimer le virus de l'hépatite c, sa préparation et son application - Google Patents

Macro-hétérocycle utilisé pour supprimer le virus de l'hépatite c, sa préparation et son application Download PDF

Info

Publication number
WO2017173960A1
WO2017173960A1 PCT/CN2017/079087 CN2017079087W WO2017173960A1 WO 2017173960 A1 WO2017173960 A1 WO 2017173960A1 CN 2017079087 W CN2017079087 W CN 2017079087W WO 2017173960 A1 WO2017173960 A1 WO 2017173960A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
compound
under
reaction
alkyl
Prior art date
Application number
PCT/CN2017/079087
Other languages
English (en)
Chinese (zh)
Inventor
王喆
王栋
陈俊杰
许曼
徐海涛
王晓光
范国钦
Original Assignee
天津长森药业有限公司
上海长森药业有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 天津长森药业有限公司, 上海长森药业有限公司 filed Critical 天津长森药业有限公司
Priority to CN201780000221.0A priority Critical patent/CN107074876B/zh
Publication of WO2017173960A1 publication Critical patent/WO2017173960A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un composé permettant de supprimer le virus de l'hépatite C (VHC), un procédé de préparation et une application pharmaceutique du composé. Le composé est représenté par la formule A. Divers substituants sont tels que définis dans la description.
PCT/CN2017/079087 2016-04-08 2017-03-31 Macro-hétérocycle utilisé pour supprimer le virus de l'hépatite c, sa préparation et son application WO2017173960A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201780000221.0A CN107074876B (zh) 2016-04-08 2017-03-31 一类抑制丙肝病毒的大环状杂环化合物及其制备和用途

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610219170.8 2016-04-08
CN201610219170.8A CN107266529A (zh) 2016-04-08 2016-04-08 一类抑制丙肝病毒的大环状杂环化合物及其制备和用途

Publications (1)

Publication Number Publication Date
WO2017173960A1 true WO2017173960A1 (fr) 2017-10-12

Family

ID=60000836

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2017/079087 WO2017173960A1 (fr) 2016-04-08 2017-03-31 Macro-hétérocycle utilisé pour supprimer le virus de l'hépatite c, sa préparation et son application

Country Status (2)

Country Link
CN (1) CN107266529A (fr)
WO (1) WO2017173960A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107074876B (zh) * 2016-04-08 2019-12-20 上海长森药业有限公司 一类抑制丙肝病毒的大环状杂环化合物及其制备和用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009134987A1 (fr) * 2008-04-30 2009-11-05 Enanta Pharmaceuticals, Inc. Composés macrocycliques contenant du difluorométhyle comme inhibiteurs du virus de l’hépatite c
CN101909446A (zh) * 2007-11-14 2010-12-08 益安药业 作为丙型肝炎病毒抑制剂的含喹喔啉的化合物
WO2011049908A2 (fr) * 2009-10-19 2011-04-28 Enanta Pharmaceuticals, Inc. Composés bismacrocycliques à titre d'inhibiteurs du virus de l'hépatite c
CN102458444A (zh) * 2009-05-13 2012-05-16 英安塔制药有限公司 用作丙型肝炎病毒抑制剂的大环化合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011209051B2 (en) * 2010-01-27 2015-01-15 AB Pharma Ltd. Polyheterocyclic compounds highly potent as HCV inhibitors
CN111116563B (zh) * 2013-06-06 2023-07-04 上海爱博医药科技有限公司 抑制丙肝病毒的化合物、药物组合物及其应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101909446A (zh) * 2007-11-14 2010-12-08 益安药业 作为丙型肝炎病毒抑制剂的含喹喔啉的化合物
WO2009134987A1 (fr) * 2008-04-30 2009-11-05 Enanta Pharmaceuticals, Inc. Composés macrocycliques contenant du difluorométhyle comme inhibiteurs du virus de l’hépatite c
CN102458444A (zh) * 2009-05-13 2012-05-16 英安塔制药有限公司 用作丙型肝炎病毒抑制剂的大环化合物
WO2011049908A2 (fr) * 2009-10-19 2011-04-28 Enanta Pharmaceuticals, Inc. Composés bismacrocycliques à titre d'inhibiteurs du virus de l'hépatite c

Also Published As

Publication number Publication date
CN107266529A (zh) 2017-10-20

Similar Documents

Publication Publication Date Title
JP6506836B2 (ja) Ｂ型肝炎ウイルス感染症の処置および予防のための新規ピリダゾンおよびトリアジノン
JP2019521972A (ja) Ｂ型肝炎抗ウイルス剤
CN108299425B (zh) 稠环衍生物、其制备方法、中间体、药物组合物及应用
AU2018250217A1 (en) ASK1 inhibitor compounds and uses thereof
WO2015124063A1 (fr) Inhibiteurs du virus de l'hepatite c et leurs utilisations dans la preparation de medicaments
TW201825490A (zh) 吡咯並［２，３－ｃ］吡啶類衍生物、其製備方法及其在醫藥上的應用
WO2006000085A1 (fr) Analogues peptidiques d'inhibiteurs de l'hepatite c
EP1709047A2 (fr) Thiourees a substitution azabenzofurane utilisees en tant qu'inhibiteurs de replication virale
UA72611C2 (uk) Похідні заміщеного піролопіридинону, корисні як інгібітори фосфодіестерази
WO2020011246A1 (fr) Composé contenant un cycle benzénique, son procédé de préparation et son utilisation
JP2014534206A (ja) Ｃ型肝炎ウイルス阻害剤
WO2020020288A1 (fr) Composé sulfoximine en tant qu'inhibiteur de protéine à bromodomaine et composition pharmaceutique et son utilisation médicale
WO2014194826A1 (fr) Composé phosphoramidate de nucléoside à trois hétérocycles fusionnés circulairement, procédé de préparation et application
EP2350039A1 (fr) Inhibiteurs de la polymérase virale
CN110461836B (zh) 一种选择性抑制激酶化合物及其用途
CN114667289A (zh) 杂芳基血浆激肽释放酶抑制剂
CN110914248A (zh) 含有胺或(硫代)酰胺的lxr调节剂
KR20180108675A (ko) 브로모도메인 억제제인 카르볼린 유도체
WO2017173960A1 (fr) Macro-hétérocycle utilisé pour supprimer le virus de l'hépatite c, sa préparation et son application
CN107074876B (zh) 一类抑制丙肝病毒的大环状杂环化合物及其制备和用途
WO2022166923A1 (fr) Composé phényldihydropyrimidine et son utilisation
WO2022116968A1 (fr) Nouvel inhibiteur de bromodomaine bet n-hétérocyclique, procédé de préparation s'y rapportant et utilisation médicale associée
CN108610332B (zh) 诱导MDM2自我降解E3泛素连接酶二聚体酯类小分子PROTACs
JP6958797B2 (ja) Ｃ型肝炎ウイルス阻害剤およびその使用
WO2016034634A1 (fr) Derives de n-aryl-2-amino-4-aryl-pyrimidines polyethers macrocycliques comme inhibiteurs de la ftl3 and jak

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17778624

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 17778624

Country of ref document: EP

Kind code of ref document: A1